NewsRelease

ScienceArticle Cites HemogloBind™ in Reticulocyte–RedBlood Cell Transition Study

MONMOUTHJUNCTION, NJ, February28, 2019-- Biotech Support Group reports on a Science article describingthe simplicity and efficiency of their hemoglobin depletiontechnology for improving LC-MS analysis from lysed reticulocytes. Thecitation is:  

Nguyen,Anthony T., et al. "UBE2Oremodels the proteome during terminal erythroid differentiation."Science357.6350 (2017): eaan0218.

Themechanisms that drive reticulocyte transition to red blood cell interminally differentiating cells remain largely unclear. Duringreticulocyte maturation, the proteome is remodeled through theprogrammed elimination of most generic constituents of the cell, inparallel with abundant synthesis of hemoglobin. The study usedmultiplexed quantitative proteomics to identify candidate substratesof UBE2O, an E2 (ubiquitin-conjugating) enzyme, in an unbiased andglobal manner. Because of the overly abundantpresence of Hemoglobin, selective depletion of Hemoglobin wasnecessary. The article states “Reticulocytes were lysedby vortexing for 5 minutes at room temperature… An additional10 bed vol of Hemoglobind™ suspension was added to the samples,which were then vortexed for another 10 min at room temperaturefollowed by 4 min of centrifugation at 10000 x g. Thesupernatants, which contain hemoglobin-depleted sample, were …processed for TMT quantification.”. Theauthors concluded that the ubiquitin-proteasome system is not simplyamplified during erythroid maturation, but suggest instead that it isbroadly reconfigured to promote remodeling of the reticulocyteproteome.

“Thelarge amount of hemoglobin in reticulocytes presents a specialchallenge for LC-MS quantitative analysis. Here is another articledemonstrating that HemogloBind™ can drastically reduce theinterference associated with large concentrations of hemoglobin,without compromising the recovery and analysis of the underlyingproteome.” states Swapan Roy, Ph.D., President and Founder ofBiotech Support Group.

Formore information on HemogloBind™, visit:

http://www.biotechsupportgroup.com/HemogloBind-Hemoglobin-Depletion-From-Hemolyzed-p/h0145.htm

Forinformation on all Hemoglobin Removal products: visit:

https://www.biotechsupportgroup.com/Articles.asp?ID=452

AboutBiotech Support Group LLC 

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ forlipid adsorption, HemogloBind™ and HemoVoid™ forhemoglobin removal, and NuGel™ for functional proteomics. Fromthese innovations, the company has acquired knowledgebase andbiomarker intellectual property assets that support discoveries ofprotein markers from blood, with special emphasis on early detectionand personalized medical decisions for cancer patients. For moreinformation, go tohttp://www.biotechsupportgroup.com

BusinessDevelopment Contact:

MattKuruc 732-274-2866, [email protected]